{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:11Z","timestamp":1790673911640,"version":"4.1.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577.<\/jats:p>","DOI":"10.1182\/blood.2019001088","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:25:12Z","timestamp":1562804712000},"page":"798-801","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"first","affiliation":[{"name":"Division of Hematology, Azienda Unit\u00e0 Sanitaria Locale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Reggio Emilia, Reggio Emilia, Italy;"},{"name":"Surgical, Medical and Dental Department of Morphological Sciences related to the Transplant, Oncology and Regenerative Medicine Department, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-5927","authenticated-orcid":false,"given":"Michele","family":"Merli","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi\u2013Azienda Socio-Sanitaria Territoriale Sette Laghi, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rattotti","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Tarantino","sequence":"additional","affiliation":[{"name":"PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy;"},{"name":"Lymphoma Unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Linfomi, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy;"},{"name":"Division of Hematology 1, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi\u2013Azienda Socio-Sanitaria Territoriale Sette Laghi, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Unit\u00e0 Sanitaria Locale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Reggio Emilia, Reggio Emilia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Cabras","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Re","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliero\u2013Universitaria di Parma, Parma, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Torresan Delamain","sequence":"additional","affiliation":[{"name":"Center of Hematology and Hemotherapy, Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Campinas, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology A, National Cancer Institute, Aviano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy;"},{"name":"Division of Hematology 1, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Unit\u00e0 Sanitaria Locale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Reggio Emilia, Reggio Emilia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deodato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-5313","authenticated-orcid":false,"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University Campus Bio-Medico, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rago","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[{"name":"Division of Hematology 2, AOU Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Defrancesco","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frigeni","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cesaretti","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Linfomi, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2020021109172853900_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020021109172853900_B2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"2020021109172853900_B3","doi-asserted-by":"crossref","first-page":"107892","DOI":"10.1100\/2012\/107892","article-title":"Prognostic assessment in patients with indolent B-cell lymphomas","volume":"2012","author":"Arcaini","year":"2012","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"2020021109172853900_B4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases [published correction appears in Br J Haematol. 2013;162(6):864]","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"issue":"23","key":"2020021109172853900_B5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"36","key":"2020021109172853900_B6","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021109172853900_B7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109172853900_B8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2020021109172853900_B9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas","volume":"94","author":"Tracy","year":"2019","journal-title":"Am J Hematol"},{"issue":"27","key":"2020021109172853900_B10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020021109172853900_B11","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2018-99-113675","article-title":"Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma [abstract]","volume":"132","author":"Freeman","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2020021109172853900_B12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"2020021109172853900_B13","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution [published online ahead of print 12 October 2018]","author":"Alderuccio","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109172853900_B14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109172853900_B15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/10\/798\/1554441\/bloodbld2019001088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/10\/798\/1554441\/bloodbld2019001088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:49:53Z","timestamp":1581414593000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/10\/798\/260629\/Early-progression-as-a-predictor-of-survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001088","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}